By PathGene Biotech · Technically reviewed by Alex Huang
Fermentation vs. Chemical Synthesis: Why the Production Route Is Shifting — and Where It Isn't
Across the active-ingredient supply chain, a growing share of production has shifted from multi-step chemical synthesis toward fermentation and enzymatic (biocatalytic) routes. It's tempting to read this as "fermentation is simply the better technology now," but that framing overstates what's actually happening. The real story is a set of trade-offs — fewer synthesis steps and less organic-solvent burden on one side, cost-efficiency and scalability on the other — and which side wins depends on the specific molecule's chemistry, not on a universal preference.
Two Different Ways to Build the Same Kind of Molecule
Chemical synthesis builds a target molecule step by step from simpler starting materials, using reagents, protecting groups, and controlled reaction conditions — reliable and well understood, but often requiring several discrete stages of reaction, workup, and purification, each consuming solvent and generating its own byproduct stream. Fermentation and biocatalysis instead use a living microorganism or an isolated/immobilized enzyme to carry out the key transformation(s) under mild aqueous conditions, often collapsing what would be several chemical steps into one biological conversion.
Fewer Steps, Less Solvent: What Biocatalysis Actually Changes
NMN (β-Nicotinamide Mononucleotide, CAS 1094-61-7) illustrates the point directly: production uses an immobilized enzyme (nicotinamide riboside kinase or nicotinamide phosphoribosyltransferase) to convert a precursor substrate into NMN in a single bioconversion step, paired with an ATP-regeneration system, rather than a chlorinated chemical route — reducing chloride-ion residues and other process-related impurities from the outset, and cutting down on the solvent-heavy purification burden that a multi-step chemical synthesis would otherwise carry. S-Equol (CAS 531-95-3) follows a similar pattern: an engineered microorganism strain carrying a natural equol-producing enzyme cascade converts plant-derived daidzein directly through dihydrodaidzein and tetrahydrodaidzein intermediates to S-equol in one fermentation/bioconversion process, rather than requiring a multi-step chemical reduction sequence.
Where Chemical Synthesis Still Holds Its Ground
The trade-off isn't one-sided. Nicotinamide Riboside Chloride (NR, CAS 23111-00-4) is manufactured through a genuinely multi-step chemical synthesis: D-ribose is protected, coupled with a nicotinamide donor under Vorbruggen-type glycosylation conditions, the beta-anomer is isolated, the protecting groups removed, and the product converted to its chloride salt and recrystallized. That's five-plus discrete chemical steps — yet it remains a commercially viable route because each step uses well-understood, inexpensive organic chemistry and readily available starting material (D-ribose), without requiring engineered production strains, bioreactor capital, or enzyme development. For a molecule where no efficient biocatalytic route has been developed — or where the chemistry is simple and well precedented — chemical synthesis can still be the more cost-efficient and readily scalable choice.
Case Study: Why S-Equol Is a Chirality Story
S-Equol is a useful case for a trade-off that goes beyond step count: chirality. Only the S-enantiomer is the biologically relevant, non-racemic form. Because the natural equol-producing enzyme cascade is inherently stereospecific, the fermentation route delivers a single, non-racemic S-configuration product directly — PathGene's material is specified at ≥99.0% chiral purity (S-isomer). A chemical synthesis route to the same molecule would be far more likely to produce a racemic (mixed R/S) product, requiring a separate, often costly chiral resolution or asymmetric-catalysis step just to isolate the desired S-form — a structural advantage that has little to do with solvent use or step count, and everything to do with the biocatalyst's inherent selectivity for this particular molecule.
Not a Universal Rule — It Depends on the Molecule
Put these examples side by side and the pattern is clear: NMN, S-Equol, and GABA (fermented via engineered Lactobacillus hilgardii) are fermentation/biocatalytic-route products where that approach offers a genuine process advantage for this specific chemistry. NR is a chemically synthesized product where a well-precedented multi-step organic route remains commercially sound. Neither is the "correct" answer in general — each reflects which approach is more efficient for that molecule's specific transformation, given current enzyme availability, chirality requirements, and the cost structure of the starting materials involved. Treating "fermentation-derived" as an automatic quality or sustainability upgrade, independent of the molecule in question, overstates what the underlying chemistry actually supports.
What This Means When You're Comparing Suppliers
For a formulator or brand evaluating raw material options, the production route is worth understanding on its own terms rather than as a marketing label. Ask what the actual manufacturing process is — fermentation, immobilized-enzyme bioconversion, or multi-step chemical synthesis — and what that implies for the impurity profile you'd expect to see on the certificate of analysis (chloride residues, residual solvents, chiral purity, related substances). The production route is a real technical fact worth knowing; it just isn't, by itself, a verdict on which material is better for your application.
Related product pages: NMN product page · NR Chloride product page
Frequently Asked Questions
Is fermentation-derived production always more sustainable or higher quality than chemical synthesis?+
Not universally. Fermentation/biocatalysis can reduce solvent use and synthesis steps for certain molecules, but chemical synthesis remains a sound, cost-efficient, and scalable route for others, such as Nicotinamide Riboside Chloride. Which is preferable depends on the specific molecule's chemistry.
Why does chirality matter for a product like S-Equol?+
Only the S-enantiomer is the biologically relevant, non-racemic form. Its inherently stereospecific fermentation route delivers this form directly, whereas a chemical synthesis route would more likely yield a racemic mixture requiring a separate chiral resolution step.
Which PathGene products are fermentation- or biocatalysis-derived?+
Examples include NMN (immobilized-enzyme bioconversion), S-Equol (whole-cell biocatalytic conversion of daidzein), and GABA (Lactobacillus hilgardii fermentation), based on their documented manufacturing processes.
Which PathGene products are made by traditional multi-step chemical synthesis?+
Nicotinamide Riboside Chloride (NR, CAS 23111-00-4) is a documented example, produced via protected-ribose glycosylation, deprotection, chloride salt formation, and recrystallization.
Does a biocatalytic/enzymatic process always cost less than chemical synthesis?+
Not necessarily. Biocatalytic routes can lower solvent and purification burden for suited molecules, but developing and scaling an enzyme or fermentation process carries its own cost, which is only worthwhile where the chemistry benefits from it.
How can I tell which production route a supplier actually used?+
Ask for the documented manufacturing process, not just a marketing description. A legitimate supplier should be able to describe the actual reaction/bioconversion steps, which also helps explain what to expect on the certificate of analysis.
Can the same target molecule sometimes be made by both fermentation and chemical synthesis?+
In principle yes for many molecules, though the resulting impurity profile, chirality, and cost structure typically differ between the two routes — which is why the specific process used, not just the final compound name, matters for evaluation.
Ready to evaluate our products?
Request a sample or send an inquiry — our R&D team responds within 24 hours.
